别名 HAP、HBV-activated protein、NR1B2 + [8] |
简介 Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to corepressors (PubMed:12554770). The RXRA/RARB heterodimer can act as a repressor on the DR1 element and as an activator on the DR5 element (PubMed:29021580). In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function (By similarity). |
作用机制 RARα激动剂 [+2] |
在研适应症 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2021-07-26 |
作用机制 GR激动剂 [+4] |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2019-04-25 |
作用机制 GR激动剂 [+3] |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 中国 |
首次获批日期2015-03-27 |
开始日期2024-04-24 |
申办/合作机构 |
开始日期2023-12-05 |
申办/合作机构- |
开始日期2023-11-27 |
申办/合作机构- |